DC Chemicals Limited
China
Product Name: Gemigliptin tartrate
Price: $Inquiry/250mg $Inquiry/100mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1374639-74-3

1374639-74-3 structure

Name: Gemigliptin tartrate
Chemical Name: Gemigliptin tartrate
CAS Number: 1374639-74-3
Molecular Formula: C₂₂H₂₅F₈N₅O₈
Molecular Weight: 639.45
Catalog: Signaling Pathways Metabolic Enzyme/Protease Dipeptidyl Peptidase
Create Date: 2020-11-28 13:55:31
Modify Date: 2024-01-08 09:38:36
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications[1][2].

Name	Gemigliptin tartrate

Description	Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase Research Areas >> Metabolic Disease
Target	IC50: 10.3 nM (human recombinant DPP-4)[2]
In Vitro	Gemigliptin tartrate dose-dependently inhibits the formation of AGE-BSA with IC50 of 11.69 mM[1]. Gemigliptin tartrate dose-dependently suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM[1]. Gemigliptin tartrate is a competitive DPP-4 inhibitor with a Ki of 7.25 nM[2].
In Vivo	Gemigliptin tartrate (100 mg/kg; i.g.; daily; for 12 weeks) inhibits AGEs formation and AGE cross-links in vivo[1]. Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys[2]. Animal Model: Male C57BL/KsJ-db/db mice (7 weeks old)[1] Dosage: 100 mg/kg Administration: Oral gavage, daily, for 12 weeks Result: Significantly reduced circulating AGE levels by 44.5% in serum.
References	[1]. Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102. [2]. Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.

Molecular Formula	C₂₂H₂₅F₈N₅O₈
Molecular Weight	639.45

1374639-74-3	1375415-82-9
911637-19-9	2407529-33-1
152854-19-8	30903-88-9
102043-41-4	1204130-47-1
22719-15-9	302-31-8